Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor–Initiating Stem Cell–Like Cells Resistant to mTORC1 Inhibition

Raymond Wu, Ramachandran Murali, Yasuaki Kabe, Samuel W. French, Yi Ming Chiang, Siyu Liu, Linda Sher, Clay C. Wang, Stan Louie, Hidekazu Tsukamoto

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Drug resistance is a major problem in the treatment of liver cancer. Mammalian Target of Rapamycin 1 (mTORC1) inhibitors have been tested for the treatment of liver cancer based on hyperactive mTOR in this malignancy. However, their clinical trials showed poor outcome, most likely due to their ability to upregulate CD133 and promote chemoresistance. The CD133+ tumor–initiating stem cell–like cells (TICs) isolated from mouse and human liver tumors are chemoresistant, and identification of an approach to abrogate this resistance is desired. In search of a compound that rescinds resistance of TICs to mTORC1 inhibition and improves chemotherapy, we identified baicalein (BC), which selectively chemosensitizes TICs and the human hepatocellular carcinoma (HCC) cell line Huh7 cells but not mouse and human primary hepatocytes. Nanobead pull-down and mass-spectrometric analysis, biochemical binding assay, and three-dimensional computational modeling studies reveal BC's ability to competitively inhibit guanosine triphosphate binding of SAR1B guanosine triphosphatase, which is essential for autophagy. Indeed, BC suppresses autophagy induced by an mTORC1 inhibitor and synergizes cell death caused by mTORC1 inhibition in TIC and Huh7 spheroid formation and in the patient-derived xenograft model of HCC. The BC-induced chemosensitization is rescued by SAR1B expression and phenocopied by SAR1B knockdown in cancer cells treated with a mTORC1 inhibitor. Conclusion: These results identify SAR1B as a target in liver TICs and HCC cells resistant to mTORC1 inhibition.

Original languageEnglish
Pages (from-to)1726-1740
Number of pages15
JournalHepatology
Volume68
Issue number5
DOIs
Publication statusPublished - 2018 Nov 1

Fingerprint

GTP Phosphohydrolases
Autophagy
Sirolimus
Stem Cells
Liver
Hepatocellular Carcinoma
Liver Neoplasms
Neoplasms
Guanosine
Guanosine Triphosphate
Drug Resistance
Heterografts
baicalein
Hepatocytes
Cell Death
Up-Regulation
Clinical Trials
Drug Therapy
Cell Line
Therapeutics

ASJC Scopus subject areas

  • Hepatology

Cite this

Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor–Initiating Stem Cell–Like Cells Resistant to mTORC1 Inhibition. / Wu, Raymond; Murali, Ramachandran; Kabe, Yasuaki; French, Samuel W.; Chiang, Yi Ming; Liu, Siyu; Sher, Linda; Wang, Clay C.; Louie, Stan; Tsukamoto, Hidekazu.

In: Hepatology, Vol. 68, No. 5, 01.11.2018, p. 1726-1740.

Research output: Contribution to journalArticle

Wu, R, Murali, R, Kabe, Y, French, SW, Chiang, YM, Liu, S, Sher, L, Wang, CC, Louie, S & Tsukamoto, H 2018, 'Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor–Initiating Stem Cell–Like Cells Resistant to mTORC1 Inhibition', Hepatology, vol. 68, no. 5, pp. 1726-1740. https://doi.org/10.1002/hep.30071
Wu, Raymond ; Murali, Ramachandran ; Kabe, Yasuaki ; French, Samuel W. ; Chiang, Yi Ming ; Liu, Siyu ; Sher, Linda ; Wang, Clay C. ; Louie, Stan ; Tsukamoto, Hidekazu. / Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor–Initiating Stem Cell–Like Cells Resistant to mTORC1 Inhibition. In: Hepatology. 2018 ; Vol. 68, No. 5. pp. 1726-1740.
@article{3a0c0bd3216946e19d6f6c4160d2eee5,
title = "Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor–Initiating Stem Cell–Like Cells Resistant to mTORC1 Inhibition",
abstract = "Drug resistance is a major problem in the treatment of liver cancer. Mammalian Target of Rapamycin 1 (mTORC1) inhibitors have been tested for the treatment of liver cancer based on hyperactive mTOR in this malignancy. However, their clinical trials showed poor outcome, most likely due to their ability to upregulate CD133 and promote chemoresistance. The CD133+ tumor–initiating stem cell–like cells (TICs) isolated from mouse and human liver tumors are chemoresistant, and identification of an approach to abrogate this resistance is desired. In search of a compound that rescinds resistance of TICs to mTORC1 inhibition and improves chemotherapy, we identified baicalein (BC), which selectively chemosensitizes TICs and the human hepatocellular carcinoma (HCC) cell line Huh7 cells but not mouse and human primary hepatocytes. Nanobead pull-down and mass-spectrometric analysis, biochemical binding assay, and three-dimensional computational modeling studies reveal BC's ability to competitively inhibit guanosine triphosphate binding of SAR1B guanosine triphosphatase, which is essential for autophagy. Indeed, BC suppresses autophagy induced by an mTORC1 inhibitor and synergizes cell death caused by mTORC1 inhibition in TIC and Huh7 spheroid formation and in the patient-derived xenograft model of HCC. The BC-induced chemosensitization is rescued by SAR1B expression and phenocopied by SAR1B knockdown in cancer cells treated with a mTORC1 inhibitor. Conclusion: These results identify SAR1B as a target in liver TICs and HCC cells resistant to mTORC1 inhibition.",
author = "Raymond Wu and Ramachandran Murali and Yasuaki Kabe and French, {Samuel W.} and Chiang, {Yi Ming} and Siyu Liu and Linda Sher and Wang, {Clay C.} and Stan Louie and Hidekazu Tsukamoto",
year = "2018",
month = "11",
day = "1",
doi = "10.1002/hep.30071",
language = "English",
volume = "68",
pages = "1726--1740",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor–Initiating Stem Cell–Like Cells Resistant to mTORC1 Inhibition

AU - Wu, Raymond

AU - Murali, Ramachandran

AU - Kabe, Yasuaki

AU - French, Samuel W.

AU - Chiang, Yi Ming

AU - Liu, Siyu

AU - Sher, Linda

AU - Wang, Clay C.

AU - Louie, Stan

AU - Tsukamoto, Hidekazu

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Drug resistance is a major problem in the treatment of liver cancer. Mammalian Target of Rapamycin 1 (mTORC1) inhibitors have been tested for the treatment of liver cancer based on hyperactive mTOR in this malignancy. However, their clinical trials showed poor outcome, most likely due to their ability to upregulate CD133 and promote chemoresistance. The CD133+ tumor–initiating stem cell–like cells (TICs) isolated from mouse and human liver tumors are chemoresistant, and identification of an approach to abrogate this resistance is desired. In search of a compound that rescinds resistance of TICs to mTORC1 inhibition and improves chemotherapy, we identified baicalein (BC), which selectively chemosensitizes TICs and the human hepatocellular carcinoma (HCC) cell line Huh7 cells but not mouse and human primary hepatocytes. Nanobead pull-down and mass-spectrometric analysis, biochemical binding assay, and three-dimensional computational modeling studies reveal BC's ability to competitively inhibit guanosine triphosphate binding of SAR1B guanosine triphosphatase, which is essential for autophagy. Indeed, BC suppresses autophagy induced by an mTORC1 inhibitor and synergizes cell death caused by mTORC1 inhibition in TIC and Huh7 spheroid formation and in the patient-derived xenograft model of HCC. The BC-induced chemosensitization is rescued by SAR1B expression and phenocopied by SAR1B knockdown in cancer cells treated with a mTORC1 inhibitor. Conclusion: These results identify SAR1B as a target in liver TICs and HCC cells resistant to mTORC1 inhibition.

AB - Drug resistance is a major problem in the treatment of liver cancer. Mammalian Target of Rapamycin 1 (mTORC1) inhibitors have been tested for the treatment of liver cancer based on hyperactive mTOR in this malignancy. However, their clinical trials showed poor outcome, most likely due to their ability to upregulate CD133 and promote chemoresistance. The CD133+ tumor–initiating stem cell–like cells (TICs) isolated from mouse and human liver tumors are chemoresistant, and identification of an approach to abrogate this resistance is desired. In search of a compound that rescinds resistance of TICs to mTORC1 inhibition and improves chemotherapy, we identified baicalein (BC), which selectively chemosensitizes TICs and the human hepatocellular carcinoma (HCC) cell line Huh7 cells but not mouse and human primary hepatocytes. Nanobead pull-down and mass-spectrometric analysis, biochemical binding assay, and three-dimensional computational modeling studies reveal BC's ability to competitively inhibit guanosine triphosphate binding of SAR1B guanosine triphosphatase, which is essential for autophagy. Indeed, BC suppresses autophagy induced by an mTORC1 inhibitor and synergizes cell death caused by mTORC1 inhibition in TIC and Huh7 spheroid formation and in the patient-derived xenograft model of HCC. The BC-induced chemosensitization is rescued by SAR1B expression and phenocopied by SAR1B knockdown in cancer cells treated with a mTORC1 inhibitor. Conclusion: These results identify SAR1B as a target in liver TICs and HCC cells resistant to mTORC1 inhibition.

UR - http://www.scopus.com/inward/record.url?scp=85054704577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054704577&partnerID=8YFLogxK

U2 - 10.1002/hep.30071

DO - 10.1002/hep.30071

M3 - Article

C2 - 29729190

AN - SCOPUS:85054704577

VL - 68

SP - 1726

EP - 1740

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -